GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BB Biotech AG (XSWX:BION) » Definitions » Debt-to-Revenue

BB Biotech AG (XSWX:BION) Debt-to-Revenue : 0.69 (As of Dec. 2023)


View and export this data going back to 1996. Start your Free Trial

What is BB Biotech AG Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

BB Biotech AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was CHF0.00 Mil. BB Biotech AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was CHF304.90 Mil. BB Biotech AG's annualized Revenue for the quarter that ended in Dec. 2023 was CHF444.68 Mil. BB Biotech AG's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.69.


BB Biotech AG Debt-to-Revenue Historical Data

The historical data trend for BB Biotech AG's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BB Biotech AG Debt-to-Revenue Chart

BB Biotech AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.09 N/A N/A N/A

BB Biotech AG Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Dec17 Dec18 Dec19 Dec20 Mar21 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A 0.69

Competitive Comparison of BB Biotech AG's Debt-to-Revenue

For the Biotechnology subindustry, BB Biotech AG's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BB Biotech AG's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BB Biotech AG's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where BB Biotech AG's Debt-to-Revenue falls into.



BB Biotech AG Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

BB Biotech AG's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 304.9) / -199.567
=-1.53

BB Biotech AG's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 304.9) / 444.68
=0.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.


BB Biotech AG Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of BB Biotech AG's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


BB Biotech AG (XSWX:BION) Business Description

Traded in Other Exchanges
Address
Schwertstrasse 6, Schaffhausen, CHE, CH-8200
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market and is one of the largest investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. BB Biotech follows a strategy of carefully screening and selecting biotechnology firms with a long-term time horizon and having established products in the marketplace. Geographically it earns key revenue from the Netherlands.
Executives
Prof. Dr. Mads Krogsgaard Thomsen Supervisory Board

BB Biotech AG (XSWX:BION) Headlines

No Headlines